OREM, Utah, Nov. 1, 2012 /PRNewswire/ -- sBioMed, an emerging leader in infection control, announced today that Stephen P. MacMillan, former Chairman and CEO of Stryker, has joined the company as Chief Executive Officer and become an owner of the company.
sBioMed has developed breakthrough patented antimicrobial technologies, offering an unprecedented level of efficacy and safety. The company's flagship product STERIPLEX SD is the first and only Clostridium difficile sporicide and broad-spectrum, one-step disinfectant, which is also remarkably safe, completely non-fuming, non-corrosive, and contains no bleach.
The technology is similar to the company's anthrax remediation product, STERIPLEX Ultra, the only EPA-registered product available that kills anthrax spores.
Brian Larson, sBioMed's cofounder and chairman, said, "After a decade of research, over 500 studies and EPA-registration, we are excited to enter the full-scale commercialization process. With Steve's leadership, we can help eliminate Healthcare-Associated Infections (HAIs) globally."
"It's rare to find a product with such revolutionary potential," MacMillan said. "STERIPLEX SD will save lives, improve healthcare delivery and protect caregivers, while reducing healthcare costs and preserving the environment. I'm also excited about the chance to work with the sBioMed team to build a very special global company based in Utah."
With the growing incidence of C. diff and other superbugs, infections are now the fourth leading killer in the U.S., at a cost to the U.S. healthcare system of tens of billions of dollars annually. Effective January 1, 2013, costs associated with HAIs will no longer be reimbursed, giving hospitals a strong incentive to eliminate HAIs. Hospitals currently employing STERIPLEX SD have charted a significant drop in HAIs.
STERIPLEX SD is EPA-registered for use on food contact surfaces (NSF D2) and can even be used
Copyright©2012 PR Newswire.
All rights reserved